---
schema_version: "secwatch.filing_event.v1"
accession: "0001070081-24-000029"
form_type: "8-K"
ticker: "PTCT"
cik: "0001070081"
company_name: "PTC THERAPEUTICS, INC."
filed_at: "2024-12-02T23:59:59+00:00"
generated_at: "2026-05-29T10:54:21.938324+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# PTC Therapeutics signs $1B upfront license deal with Novartis for PTC518 HD program

## Summary
- PTC receives $1.0B upfront; eligible for up to $1.9B in development, regulatory and sales milestones.
- PTC will receive 40% share of U.S. profits/losses and tiered double-digit royalties on ex-U.S. sales.
- Novartis will assume global development, manufacturing and commercialization after placebo-controlled portion of PIVOT-HD trial.
- Transaction expected to close in Q1 2025, subject to regulatory clearance and customary conditions.
- PTC intends to use proceeds to expand splicing platform and support commercial/development portfolio.

## SEC filing metadata
- accession: 0001070081-24-000029
- form_type: 8-K
- ticker: PTCT
- cik: 0001070081
- company_name: PTC THERAPEUTICS, INC.
- filed_at: 2024-12-02T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070081/000107008124000029/0001070081-24-000029-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070081/000107008124000029/tmb-20241127x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001070081-24-000029
- JSON: https://secwatch.observer/filing/0001070081-24-000029.json
- Plain text: https://secwatch.observer/filing/0001070081-24-000029.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.